Welcome to our dedicated page for Avita Medical SEC filings (Ticker: RCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AVITA Medical, Inc. (RCEL) SEC filings page brings together the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, annual reports on Form 10-K, and quarterly reports on Form 10-Q. As a therapeutic acute wound care company focused on the RECELL System and related wound care technologies, AVITA Medical uses these filings to report on its financial condition, capital structure, governance, and material business developments.
In its Form 8-K filings, AVITA Medical has disclosed material definitive agreements such as senior secured credit facilities, amendments to existing credit agreements, and related covenants tied to trailing twelve-month revenue. These documents detail loan terms, revenue requirements, warrant issuances, and security interests in company assets. Other 8-K reports cover equity placements, including CHESS Depositary Interests issued to institutional and professional investors, and governance matters such as board appointments, executive transitions, and director compensation arrangements.
Periodic reports like the Form 10-K and Form 10-Q (accessible from this filings stream when available) provide broader information on AVITA Medical’s business, including discussion of its therapeutic acute wound care platform, risk factors, and consolidated financial statements. Investors can review these filings to understand how the company describes its RECELL System, PermeaDerm, and Cohealyx products, as well as its regulatory environment and key risk considerations.
Stock Titan’s platform enhances access to these documents with AI-powered summaries that explain the significance of complex filings, from credit agreements and warrant terms to revenue covenants and equity raises. Real-time updates from EDGAR ensure that new 8-K, 10-Q, 10-K, and Form 4 insider transaction reports are available as they are filed, while AI-generated highlights help readers quickly identify items related to financing, governance, and operational strategy for AVITA Medical.
AVITA Medical, Inc. director Woody Joseph Fralin filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director of the company and reports no buy, sell, acquire, or dispose transactions in AVITA Medical, Inc. securities.
AVITA Medical, Inc. Chief Financial Officer David D. O'Toole reported an open-market purchase of 3,000 shares of common stock on February 19, 2026 at $4.15 per share. Following this buy, his directly held stake increased to 140,127 shares, which includes unvested restricted stock units.
AVITA Medical, Inc. CFO David D. O'Toole reported equity compensation awards consisting of stock options and restricted stock units. He acquired 155,510 stock options with an exercise right to buy common shares, and 105,470 shares of common stock in the form of restricted stock units, both at a stated price of $0.00 per share.
The RSUs represent rights to receive one share of common stock each, vesting in three equal annual installments starting 12 months after the February 18, 2026 grant date. The stock options also vest in three equal annual installments beginning on the first anniversary of the same grant date, aligning his compensation with longer-term company performance.
AVITA Medical, Inc. reported that Chief Legal Officer Nicole Kelsey received equity awards consisting of stock options and restricted stock units. She was granted stock options for 145,060 shares at an exercise price of
The restricted stock units each represent the right to receive one share of Common Stock and vest in three equal annual installments beginning 12 months after the
AVITA Medical, Inc. reports in its annual filing that it remains a high-growth, loss-making acute wound care company built around its RECELL autologous cell harvesting platform and new products Cohealyx and PermeaDerm.
The company posted a net loss of $48.6 million in 2025 and has an accumulated deficit of $408.4 million, while targeting long-term profitability through broader use of RECELL in burns, traumatic and surgical wounds and international expansion. AVITA added a new senior secured credit facility of up to $60 million, drawing $50 million and using part of the proceeds to refinance prior debt. It emphasizes extensive FDA approvals, growing clinical and health-economic evidence, and a sizable patent and trademark portfolio as competitive strengths, but warns that execution, reimbursement, regulatory, manufacturing, cybersecurity, and high leverage risks could materially affect results.
AVITA Medical reported fourth quarter 2025 revenue of
For full-year 2025, revenue grew about
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership of Avita Medical Inc common stock. Vanguard reports beneficially owning 1,444,579 shares, representing 4.73% of the outstanding common stock, with shared voting power over 190,616 shares and shared dispositive power over all 1,444,579 shares.
Vanguard indicates it holds the securities in the ordinary course of business and not to change or influence control of Avita Medical. The filing notes an internal realignment on January 12, 2026, after which certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately.
AVITA Medical, Inc. entered into a new five-year senior secured credit facility of up to
The loan bears interest at the SOFR rate (with a minimum of
As part of the financing, AVITA agreed to issue a 10-year warrant to purchase up to 500,000 shares of common stock, with an additional 150,000 shares becoming issuable if the additional loan commitment is drawn. The warrant’s exercise price is based on the 10-day volume-weighted average price and is subject to shareholder approval and Australian Securities Exchange requirements. AVITA also furnished a press release updating expected fourth quarter and full-year 2025 revenue and providing 2026 revenue guidance.
AVITA Medical, Inc. appointed experienced healthcare executive Joe Woody to its Board of Directors, effective January 1, 2026, to serve until the 2026 Annual Meeting of Stockholders. He will sit on each of the Board’s committees and has been determined to be an independent director under applicable standards. The company states that he has no appointment-related arrangements, family relationships with directors or executives, or material related-party transactions requiring disclosure.
Woody brings more than two decades of medical technology leadership, including serving as CEO of Avanos Medical and President and CEO of Acelity Holdings, as well as senior roles at Covidien and Smith & Nephew and long-term service on the AdvaMed board. Under an offer letter effective January 1, 2026, he will receive $92,500 in annual cash compensation for Board service and an initial equity grant valued at $210,000, with about 30% in stock options and 70% in restricted stock units, plus eligibility for annual equity grants, all subject to shareholder approval.
AVITA Medical (RCEL) filed its Q3 2025 10‑Q, reporting lower revenue and a going concern warning. Total revenue was $17.1 million for the quarter, down from $19.5 million a year ago. Net loss was $13.2 million versus $16.2 million in the prior year period. For the nine months, revenue reached $54.0 million and net loss was $37.0 million.
Cash, cash equivalents, and marketable securities were $23.3 million as of September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern due to expected non‑compliance with a minimum cash covenant under its senior secured credit facility. The loan facility balance of $42.4 million was classified as current. AVITA obtained revenue covenant waivers for Q1–Q3 2025 and amended future thresholds.
To bolster liquidity, AVITA completed an August 12, 2025 private placement raising $14.8 million gross (3,440,377 common share equivalents via 17,201,886 CDIs). Shares outstanding were 30,493,111 as of November 3, 2025. Lease revenue from RECELL GO devices was $165,000 in Q3, with product sales the primary driver of revenue.